Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: A prospective phase II study in Japanese patients

International Journal of Hematology

Volumn 84, Issue 1, 2006, Pages 83-89

  Kohno, Akio ^a,g,h   Morishita, Yoshihisa ^a,g   Iida, Hiroatsu ^b,g   Sakamaki, Hisashi ^c   Yokozawa, Toshiya ^d,g   Kitaori, Kenjiro ^e,g   Ozeki, Kazutaka ^a,g   Matsuo, Keitaro ^f,g   Sao, Hiroshi ^b,g  

^a JA Aichi Showa Hospital   (Japan)

^b Meitetsu Hospital   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g Nagoya Blood and Marrow Transplantation Group   (Japan)

^h Showa General Hospital   (Japan)

Author keywords

Bone marrow transplantation; Cyclosporin A; Graft versus host disease; Methotrexate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUSULFAN; CORTICOSTEROID; CYCLOSPORIN A; CYTARABINE; HLA ANTIGEN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TSUKUBAENOLIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOTOXICITY; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; JAPAN; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG TOXICITY; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHORT COURSE THERAPY; SIBLING; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; ALLOTRANSPLANTATION; ASIAN; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33748641395     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05171     Document Type: Article

References (31)

1. Rowlings PA, Przepiorka D, Klein JP, et al. TBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855-864.
2. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-1472.
3. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821-1828.
4. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
5. Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation: multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant. 1991;7:453-459.
6. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720-1728.
7. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
8. Ringden O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1996;18:921-929.
9. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533.
10. Ringden O, Labopin M, Gluckman E, et al. Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Transplant Proc. 1997;29:733-734.
11. Zikos P, Van Lint MT, Lamparelli T, et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica. 1998;83:896-903.
12. Munker R, Gunther W, Kolb HJ. New concepts about graft-versus-host and graft-versus-leukaemia-reactions: a summary of the 5th International Symposium held in Munich, 21 and 22 March 2002. Bone Marrow Transplant. 2002;30:549-556.
13. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
14. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73:1729-1734.
15. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant. 1997;19:759-764.
16. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77:1423-1428.
17. Morishima Y, Morishita Y, Tanimoto M, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood. 1989;74:2252-2256.
18. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81:1094-1101.
19. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
20. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
21. Greenwood MA. The natural duration of cancer. Rep Public Health Med Subjects. 1926;33:1-26.
22. Stockschlaeder M, Storb R, Pepe M, et al. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol. 1992;80:49-54.
23. Carlens S, Aschan J, Remberger M, et al. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplant. 1999;24:629-635.
24. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000;95:1572-1579.
25. Atkinson K, Biggs JC, Hayes J, et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol. 1983;54:59-67.
26. Hows JM, Chipping PM, Fairhead S, et al. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A. Br J Haematol. 1983;54:69-78.
27. Atkinson K, Biggs J, Dodds A, Concannon A. Cyclosporine-associated hepatotoxicity after allogeneic marrow transplantation in man: differentiation from other causes of posttransplant liver disease. Transplant Proc. 1983;15:2761-2767.
28. Kagawa Y, Sawada J, Yamada S, et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull. 2003;26:1115-1119.
29. Shah AK. Cyclosporine A neurotoxicity among bone marrow transplant recipients. Clin Neuropharmacol. 1999;22:67-73.
30. Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation. 1999;67:1133-1137.
31. Byrne JL, Stainer C, Hyde H, et al. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant. 1998;22:541-545.